Insulin Resistance and Diabetes in Hypertension

Comprehensive Hypertension

Volumn , Issue , 2007, Pages 681-692

  Mugo, Maryann N ^a   Link, Daniel ^b   Stump, Craig S ^c,d   Sowers, James R ^e  

^a University of Missouri   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF ARIZONA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882857802     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-03961-1.50058-1     Document Type: Chapter

References (75)

1. National Center for Chronic Disease Prevention and Health Promotion. (2003) National diabetes fact sheet: general information and national estimates on diabetes in the United States Atlanta, GA: Centers for Disease Control
2. Healthy People 2010. Diabetes Progress Review, 2002 2005.
3. M Mugo and JR Sowers (2004) Metabolic syndrome: implications of race and ethnicity. Ethn Dis 14 S2-31.
4. JR Sowers, M Epstein and ED Frohlich (2001) Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 37 1053-1059.
5. JR Sowers (2004) Treatment of hypertension in patients with diabetes. Arch Intern Med 164-167. 1850
6. KK Ho, KM Anderson, WB Kannel, et al. (1993) Congestive heart failure/myocardial responses/valvular heart disease: survival after the onset of congestive heart failure in the Framingham Heart Study subjects. Circulation 88(1), 107-115.
7. ES Ford, WH Giles and AH Mokdad (2004) Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 27 2444-2449.
8. KG Alberti, P Zimmet and J Shaw (2005) IDF Epidemiology Task Force Consensus Group The metabolic syndrome—a new worldwide definition. Lancet 366 1059-1062.
9. SI McFarlane, M Banerji and JR Sowers (2001) Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 86 713-718.
10. AS Tan, S Kuppuswamy, A Whaley-Connell, et al. (2004) Recommendations for special populations: the treatment of hypertension in diabetes mellitus. Endocrinologist 14 368-381.
11. JR Sowers (2003) Obesity as a cardiovascular risk factor. Am J Med 115(Suppl 8A), 37S-41S.
12. A Aneja, F El-Atat, SI McFarlane and JR Sowers (2004) Hypertension and obesity. Recent Prog Horm Res 59 169-205.
13. CC Wang, ML Goalstone and B Draznin (2004) Molecular mechanisms of insulin resistance that impact cardiovascular biology. Diabetes 53 2735-2740.
14. JR Sowers (1997) Insulin and insulin-like growth factor in normal and pathological cardiovascular physiology. Hypertension 29 691-699.
15. JR Sowers (2004) Insulin resistance and hypertension. Am J Physiol Circ Physiol 286 H1597-H1602.
16. L Lind, C Berne and H Lithell (1995) Prevalence of insulin resistance in essential hypertension. J Hypertens 13 1457-1462.
17. A Marigliano, et al. (1990) Insulinemia and blood pressure. Relationships in patients with primary and secondary hypertension, and with or without glucose metabolism impairment. Am J Hypertens 3 521-526.
18. FS Facchini, YD Chen and C Clinkingbeard (1992) Insulin resistance, hyperinsulinemia and dyslipidemia in non-obese individuals with a family history of hypertension. Am J Hypertens 5 694-699.
19. JR Sowers and CS Stump (2004) Insights into the biology of diabetic vascular disease: what's new? Am J Hypertens 17 2S-6S.
20. SN Stas, FA El-Atat and JR Sowers (2004) Pathogenesis of hypertension in diabetes. Rev Endocrinol Metab Disord 5 221-225.
21. D Pollock (2005) Endothelin, angiotensin and oxidative stress in hypertension. Hypertension 45 477-480.
22. GF DiBona (2004) The sympathetic nervous system and hypertension, recent developments. Hypertension 43 147-150.
23. C Weyer, et al. (2004) Ethnic differences in insulinemia and sympathetic tone as links between obesity and blood pressure. Hypertension 36 531-537.
24. T Ogihara, T Asano, K Ando, et al. (2002) Angiotensin II enhanced insulin resistance is associated with enhanced insulin signaling. Hypertension 40 872-879.
25. JR Sowers (2004) Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 286 H1597-H1602.
26. S Dimmeler, V Rippmann, U Weiland, et al. (1999) Angiotensin II induces apoptosis of human endothelial cells. Protective effect of nitric oxide. Circ Res 81 970-976.
27. T Watanabe, T Barker and B Berk (2005) Angiotensin II and the endothelium. Hypertension 45 163-169.
28. JL Mehta, DY Li, H Yang and MK Raizada (2002) Angiotensin II and IV stimulate expression and release of plasminogen activator inhibitor-1 in cultured human coronary artery endothelial cells. J Cardiovasc Pharmacol 39 789-794.
29. R Tamarat, JS Silvestre, M Durie and BI Levy (2002) Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor and inflammation related pathways. Lab Invest 82 747-756.
30. MB Marrero, D Fulton, D Stepp and DM Stern (2004) Angiotension II-induced insulin resistance and protein tyrosine phosphatases. Arterioscler Thromb Vasc Biol 24 2009-2013.
31. S Yusuf, P Sleight, J Pogue, et al. (2000) Effects of the angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 145-153.
32. B Lassegue and RE Clempus (2003) Vascular NAD(P)H oxidase: specific features, expression and regulation. Am J Physiol Integr Comp Physiol 285 R277-R297.
33. R Touyz (2004) Reactive oxygen species, vascular oxidative stress, and redox signalling in hypertension: what is the clinical significance? Hypertension 44 248-252.
34. JR Sowers (2004) Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 286 H1597-H1602.
35. SA Huber, P Sakkinen, D Conze, et al. (1999) Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol 19 2364-2367.
36. GS Hotamisligil, P Peraldi, A Budavari, et al. (1996) IRS-1 mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha and obesity induced insulin resistance. Science 271 665-668.
37. P Dandona (2002) A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation and atherosclerosis in diabetes. Am J Cardiol 90 27G-33G.
38. P Libby and PM Ridker (2004) Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med 116(Suppl 1), 9–16
39. JR Sowers (2004) Stroke in patients with diabetes. J Clin Hypertens (Greenwich) 6 62-63.
40. RL Sacco (2002) Reducing the risk of stroke in diabetes: what have we learned that is new? Diabetes Obes Metab 4(Suppl 1), S27-S34.
41. J Tuomilehto and D Rastenyte (1999) Diabetes and glucose intolerance as risk factors for stroke. J Cardiovasc Risk 6 241-249.
42. UK Prospective Diabetes Study Group. (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317 703-713.
43. Heart Outcomes Prevention Evaluation Study Investigators. (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355 253-259.
44. LH Lindholm, H Ibsen, B Dahlof, et al. (2002) Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized controlled trial against atenolol. Lancet 359 1004-1010.
45. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 2981-2997.
46. AV Chobanian, et al. (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289 2560-2572.
47. MN Mugo and JR Sowers (2005) Early and aggressive treatment of complex hypertension. J Clin Hypertens (Greenwich) 7 8-10.
48. G Bakris, M Williams, L Dworkin, et al. (2000) Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 36 646-661.
49. G. Eknoyan, et al. (2003) Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis 42 617-622.
50. HC Gerstein, et al. (2000) Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators. Diabetes Care 23(Suppl 2), B35-B39.
51. JR Sowers and S Haffner (2002) Treatment of cardiovascular and renal risk factors in the diabetic hypertensive. Hypertension 40 781-788.
52. T Ohkubo, A Hozawa, J Yamaguchi, et al. (2002) Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. J Hypertens 20 2183-2189.
53. ZY Fang, JB Prins and TH Marwick (2004) Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 25 543-567.
54. ED Frohlich and JR Sowers (2003) Management of diabetic and hypertensive cardiovascular disease. Curr Hypertens Rep 5 309-315.
55. J Tuomilehto, J Lindstrom, JG Eriksson, et al. (2001) Prevention of type 2 diabetes by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344 1343-1350.
56. G Hu, NC Barengo, J Tuomilehto, et al. (2004) Relationship of physical activity and body mass index to the risk of hypertension: a prospective study in Finland. Hypertension 43 25-30.
57. SP Whelton, A Chin, X Xin, et al. (2002) Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med 136 493-503.
58. D Haire-Joshu, RE Glasgow and TL Tibbs (2004) Smoking and diabetes. Diabetes Care 27(Suppl 1), S74-S75.
59. Heart Outcomes Prevention Evaluation Study Investigators. (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355 253-259.
60. L Niskanen, T Hedner, L Hansson, et al. (2001) Reduced cardiovascular morbidityand mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with diuretic/beta-blocker based regimen: a sub-analysis of the Captopril Prevention Project. Diabetes Care 24 2091-2096.
61. GL Bakris and JR Sowers (2002) Microalbuminuria in diabetes: focus on cardiovascular and renal risk reduction. Curr Diabetes Rep 2 258-262.
62. GL Bakris and MR Weir (2000) Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 160 685-693.
63. B Dahlof, RB Devereux, SE Kjeldsen, et al. (2002) Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 359 995-1003.
64. G Bakris, M Weir and S Shanifar (2003) Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 163 1555-1565.
65. CE Mogensen, S Neldam, I Tiakkanen, et al. (2000) Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the Candesartan and Lisinopril Microalbuminuria (CALM) study. BMJ 321 1440-1444.
66. P Verdecchia, G Reboldi and F Angeli (2004) Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 43 963-969.
67. G Bakris and JR Sowers (2004) When does new onset diabetes resulting from antihypertensive therapy increase cardiovascular risk? Hypertension 43 941-942.
68. JB Kostis, J Lawrence-Nelson, R Ranjan, et al. (2001) Association of increased pulse pressure with the development of heart failure in SHEP. Systolic Hypertension in the Elderly (SHEP) Cooperative Research Group. Am J Hypertens 14 798-803.
69. SI McFarlane, et al. (2002) Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care 25 718-723.
70. CJ Pepine, EM Handberg, RM Cooper-DeHoff, et al. (2003) A calcium antagonist vs. non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 290 2805-2816.
71. WH Birkenhager, JA Staessen, J Gasowski, et al. (2000) Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst-Eur) trial. J Nephrol 13 232-237.
72. B Carlberg, O Samuelsson and LH Lindholm (2004) Ateolol in hypertension: is it a wise choice? Lancet 354 1684-1689.
73. S Jacob, B Balletshofer, EJ Henriksen, et al. (1999) Beta blocking agents in patients with insulin resistance: effects of vasodilating beta-blockers. Blood Press 8 261-268.
74. W Fassbinder, O Quarder and A Waltz (2005) Treatment with carvedilol is associated with a significant reduction in microalbuminuria: a multicenter randomized study. Int J Clin Pract 53 519-522.
75. AF Khoury and NM Kaplan (1991) Alpha-blocker therapy for hypertension. An unfulfilled promise. JAMA 266 394-398.